Jin-Jun Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jin-Jun Rao has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Pei-Liang Zhao
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China
3 shared publications Fang Yang
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China
2 shared publicationsLin Chen
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China
2 shared publications- Shu-Guang Wu
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
2 shared publications Wei Xu
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
2 shared publicationsWen-Wei You
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China
2 shared publications
Latest Publications
- 1 September 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 102, 104076
Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors
- 1 September 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 102, 104076
Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors
- 1 January 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (1) , 22-27
Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors
- 1 January 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (1) , 22-27
Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors
- Open Access
- 1 December 2015
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 16 (1) , 56
Ameliorative effects of Xue-Fu-Zhu-Yu decoction, Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode
Xue-Fu-Zhu-Yu decoction (XFZYD), Tian-Ma-Gou-Teng-Yin (TMGTY) and Wen-Dan decoction (WDD) are Chinese herbal formulas used to treat hypertension and cardiovascular diseases in traditional Chinese medicine (TCM). The goal of our study is to determine if XFZYD, TMGTY or WDD treatment ameliorated myocardial fibrosis in spontaneously hypertensive rats (SHRs) and to identify the mechanisms underlying any beneficial effects observed during the courses of the investigation. Forty-five 12-week-old male spontaneously hypertensive rats and five age-matched male Wistar-Kyoto control rats were studied for 16 weeks. Each day 6 g∙kg−1 or 12 g∙kg−1 of XFZYD, TMGTY or WDD was orally administered at the indicated dose, and the systolic blood pressure (SBP) of all rats was measured using the tail-cuff method. Collagen levels were measured via hydroxyproline content assays and histological examination. Transforming growth factor beta-1 (TGF-β1) protein levels were determined via immunhistochemical and Western blot analysis. TGF-β1 mRNA levels were assessed using real-time reverse transcription polymerase chain reaction. Systolic blood pressure was unaffected, but collagen and TGF-β1 levels in SHRs treated with captopril and XFZYD (12 g∙kg−1) were significantly reduced when compared with untreated control SHRs. Administration of 12 g∙kg−1 XFZYD increased myocardial cell protection and decreased TGF-β1 mRNA and protein expression when compared with the other SHR treatment groups. XFZYD treatment demonstrated a superior ability to reverse myocardial fibrosis when compared with WDD or TMGTY treatment in SHRs. XFZYD also decreased TGF-β1 mRNA and protein expression, suggesting that the TGF-β1 signaling pathway plays a role in the therapeutic effects of XFZYD treatment.
- 1 December 2015
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 16 (1) , 56
Open AccessAmeliorative effects of Xue-Fu-Zhu-Yu decoction, Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode
Xue-Fu-Zhu-Yu decoction (XFZYD), Tian-Ma-Gou-Teng-Yin (TMGTY) and Wen-Dan decoction (WDD) are Chinese herbal formulas used to treat hypertension and cardiovascular diseases in traditional Chinese medicine (TCM). The goal of our study is to determine if XFZYD, TMGTY or WDD treatment ameliorated myocardial fibrosis in spontaneously hypertensive rats (SHRs) and to identify the mechanisms underlying any beneficial effects observed during the courses of the investigation. Forty-five 12-week-old male spontaneously hypertensive rats and five age-matched male Wistar-Kyoto control rats were studied for 16 weeks. Each day 6 g∙kg−1 or 12 g∙kg−1 of XFZYD, TMGTY or WDD was orally administered at the indicated dose, and the systolic blood pressure (SBP) of all rats was measured using the tail-cuff method. Collagen levels were measured via hydroxyproline content assays and histological examination. Transforming growth factor beta-1 (TGF-β1) protein levels were determined via immunhistochemical and Western blot analysis. TGF-β1 mRNA levels were assessed using real-time reverse transcription polymerase chain reaction. Systolic blood pressure was unaffected, but collagen and TGF-β1 levels in SHRs treated with captopril and XFZYD (12 g∙kg−1) were significantly reduced when compared with untreated control SHRs. Administration of 12 g∙kg−1 XFZYD increased myocardial cell protection and decreased TGF-β1 mRNA and protein expression when compared with the other SHR treatment groups. XFZYD treatment demonstrated a superior ability to reverse myocardial fibrosis when compared with WDD or TMGTY treatment in SHRs. XFZYD also decreased TGF-β1 mRNA and protein expression, suggesting that the TGF-β1 signaling pathway plays a role in the therapeutic effects of XFZYD treatment.
- 5 August 2010
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (8) , 953-962
Geniposide inhibits high glucose-induced cell adhesion through the NF-κB signaling pathway in human umbilical vein endothelial cells
Aim: Methods: Results: Conclusion:
- 5 August 2010
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (8) , 953-962
Geniposide inhibits high glucose-induced cell adhesion through the NF-κB signaling pathway in human umbilical vein endothelial cells
Aim: Methods: Results: Conclusion:
- 16 July 2009
- Published by Wiley in Phytotherapy Research
- Vol. 24 (2) , 219-224
Effect of astragaloside IV on hepatic glucose‐regulating enzymes in diabetic mice induced by a high‐fat diet and streptozotocin
Aim: Hepatic glycogen phosphorylase (GP) and glucose‐6‐phosphatase (G6Pase) are important in control of blood glucose homeostasis, and are considered to be potential targets for antidiabetic drugs. Astragaloside IV has been reported to have a hypoglycemic effect. However, the biochemical mechanisms by which astragaloside IV regulates hepatic glucose‐metabolizing enzymes remain unknown. The present study examines whether GP and G6Pase mediate the hypoglycemic effect of astragaloside IV. Methods: Type 2 diabetic mice were treated with astragaloside IV for 2 weeks. Blood glucose and insulin levels were measured by a glucometer and the ELISA method, respectively. Total cholesterol (TC) and triglyceride (TG) levels were determined using LabassayTM kits. Activities of hepatic GP and G6Pase were measured by the glucose‐6‐phosphate dehydrogenase‐coupled reaction. The mRNA and protein levels of both enzymes were determined by real‐time RT‐PCR and Western blotting. Results: Astragaloside IV at 25 and 50 mg/kg significally decreased the blood glucose, TG and insulin levels, and inhibited the mRNA and protein expression as well as enzyme activity of GP and G6Pase in diabetic mice. Conclusions: Astragaloside IV exhibited a hypoglycemic effect in diabetic mice. The hypoglycemic effect of this compound may be explained, in part, by its inhibition of hepatic GP and G6Pase activities. Copyright © 2009 John Wiley & Sons, Ltd.
- 16 July 2009
- Published by Wiley in Phytotherapy Research
- Vol. 24 (2) , 219-224
Effect of astragaloside IV on hepatic glucose‐regulating enzymes in diabetic mice induced by a high‐fat diet and streptozotocin
Aim: Hepatic glycogen phosphorylase (GP) and glucose‐6‐phosphatase (G6Pase) are important in control of blood glucose homeostasis, and are considered to be potential targets for antidiabetic drugs. Astragaloside IV has been reported to have a hypoglycemic effect. However, the biochemical mechanisms by which astragaloside IV regulates hepatic glucose‐metabolizing enzymes remain unknown. The present study examines whether GP and G6Pase mediate the hypoglycemic effect of astragaloside IV. Methods: Type 2 diabetic mice were treated with astragaloside IV for 2 weeks. Blood glucose and insulin levels were measured by a glucometer and the ELISA method, respectively. Total cholesterol (TC) and triglyceride (TG) levels were determined using LabassayTM kits. Activities of hepatic GP and G6Pase were measured by the glucose‐6‐phosphate dehydrogenase‐coupled reaction. The mRNA and protein levels of both enzymes were determined by real‐time RT‐PCR and Western blotting. Results: Astragaloside IV at 25 and 50 mg/kg significally decreased the blood glucose, TG and insulin levels, and inhibited the mRNA and protein expression as well as enzyme activity of GP and G6Pase in diabetic mice. Conclusions: Astragaloside IV exhibited a hypoglycemic effect in diabetic mice. The hypoglycemic effect of this compound may be explained, in part, by its inhibition of hepatic GP and G6Pase activities. Copyright © 2009 John Wiley & Sons, Ltd.